A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE)

References

• Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. J Neurochem 1995;65:292–300.
   PubMed Web of Science ®Google Scholar
• Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71:505–8.
   PubMed Web of Science ®Google Scholar
• Campora M, Francesconi V, Schenone S, et al. Journey on naphthoquinone and anthraquinone derivatives: new insights in Alzheimer’s disease. Pharmaceuticals 2021;14:33.
   Web of Science ®Google Scholar
• Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis 2020;12:1179573520907397.
   Web of Science ®Google Scholar
• Savelieff MG, Nam G, Kang J, et al. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev 2019;119:1221–322.
   PubMed Web of Science ®Google Scholar
• Mullard A. Controversial Alzheimer’s drug approval could affect other diseases. Nature 2021;595:162–3.
   PubMed Web of Science ®Google Scholar
• Mullard A. Landmark Alzheimer’s drug approval confounds research community. Nature 2021;594:309–10.
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Lee HG, Zhu X, et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 2006;111:503–9.
   PubMed Web of Science ®Google Scholar
• Przybyłowska M, Kowalski S, Dzierzbicka K, Inkielewicz-Stepniak I. Inkielewicz-Stepniak I. Therapeutic potential of multifunctional tacrine analogues. Curr Neuropharmacol 2019;17:472–90.
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47.
   PubMed Web of Science ®Google Scholar
• Bols M. 1-Aza sugars,† apparent transition state analogues of equatorial glycoside formation/cleavage. Acc Chem Res 1998;31:1–8.
   Web of Science ®Google Scholar
• Lillelund VH, Jensen HH, Liang X, Bols M. Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev 2002;102:515–53.
   PubMed Web of Science ®Google Scholar
• Asano N, Nash RJ, Molyneux RJ, Fleet GWJ. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron Asymmetry 2000;11:1645–80.
   Web of Science ®Google Scholar
• Sugimoto S, Nakajima H, Kosaka K, Hosoi H. Review: miglitol has potential as a therapeutic drug against obesity. Nutr Metab 2015;12:51.
   Google Scholar
• Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017;18:441.
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Schiffmann R, Kathleen Nicholls K. Migalastat for the treatment of Fabry disease. Expert Opin Orphan Drugs 2018;6:303–9.
   Web of Science ®Google Scholar
• Noel A, Ingrand S, Barrier L. Anti-amyloidogenic effects of glycosphingolipid synthesis inhibitors occur independently of ganglioside alterations. Mol Cell Neurosci 2016;75:63–70.
   PubMed Web of Science ®Google Scholar
• Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991;253:872–9.
   PubMed Web of Science ®Google Scholar
• Nicolet Y, Lockridge O, Masson P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141–7.
   PubMed Web of Science ®Google Scholar
• Macdonald IR, Martin E, Rosenberry TL, Darvesh S. Probing the peripheral site of human butyrylcholinesterase. Biochemistry 2012;51:7046–53.
   PubMed Web of Science ®Google Scholar
• Nachon F, Ehret-Sabatier L, Loew D, et al. Trp82 and Tyr332 are involved in two quaternary ammonium binding domains of human butyrylcholinesterase as revealed by photoaffinity labeling with [3H]DDF†. Biochemistry 1998;37:10507–13.
   PubMed Web of Science ®Google Scholar
• Decroocq C, Stauffert F, Pamlard O, et al. Iminosugars as a new class of cholinesterase inhibitors. Bioorg Med Chem 2015;25:830–3.
   Web of Science ®Google Scholar
• Liao CR, Rak M, Lund J, et al. SynchrotronFTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer’s disease brain. Analyst 2013;138:3991–7.
   PubMed Web of Science ®Google Scholar
• Zueva I, Dias J, Lushchekina S, et al. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer’s disease. Neuropharmacology 2019;155:131–41.
   PubMed Web of Science ®Google Scholar
• Olsen JI, Plata GB, Padrón JM, et al. Selenoureido-iminosugars: a new family of multitarget drugs. Eur J Med Chem 2016;123:155–60.
   PubMed Web of Science ®Google Scholar
• de Santana QLO, Santos Evangelista TC, Imhof P, et al. Tacrine-sugar mimetic conjugates as enhanced cholinesterase inhibitors. Org Biomol Chem 2021;19:2322–37.
   PubMed Web of Science ®Google Scholar
• Ahuja-Casarín AI, Merino-Montiel P, Vega-Baez JL, et al. Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. J Enzyme Inhib Med Chem 2021;36:138–46.
   PubMed Web of Science ®Google Scholar
• Singh A, Sharma S, Arora S, et al. New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation. Bioorg Med Chem Lett 2020;30:127477.
   PubMed Web of Science ®Google Scholar
• Campora M, Canale C, Gatta E, et al. Multitarget biological profiling of new naphthoquinone and anthraquinone-based derivatives for the treatment of Alzheimer’s disease. ACS Chem Neurosci 2021; 12:447–61.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Moutayakine A, Marques C, López Ó, et al. Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer’s disease. Bioorg Med Chem 2022;68:116807.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Wennekes T, van den Berg R, Donker W, et al. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem 2007;72:1088–97.
   PubMed Web of Science ®Google Scholar
• Decroocq C, Rodríguez-Lucena D, Russo V, et al. The multivalent effect in glycosidase inhibition: probing the influence of architectural parameters with cyclodextrin-based iminosugar click clusters. Chem Eur J 2011;17:13825–31.
   PubMed Web of Science ®Google Scholar
• Lopéz Ó, Bols M. Anomer-selective glycosidase inhibition by 2-N-alkylated 1-azafagomines. ChemBioChem 2007;8:657–61.
   PubMed Web of Science ®Google Scholar
• Saxena A, Redman AM, Jiang X, et al. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Chem Biol Interact 1999;119-120:61–9.
   PubMed Web of Science ®Google Scholar
• Holdgate G, Meek T, Grimley R. Mechanistic enzymology in drug discovery: a fresh perspective. Nat Rev Drug Discov 2018;17:115–32.
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 1974;137:143–4.
   PubMed Web of Science ®Google Scholar
• Zhang X, Dai H, Yan H, et al. B − H···π interaction: a new type of nonclassical hydrogen bonding. J Am Chem Soc 2016;138:4334–7.
   PubMed Web of Science ®Google Scholar